

Introduction to Cardiac MRI

Fawzi Ameer, MD

General Cardiologist
Heart and Vascular Institute
Monument Health



Objectives

Understand


Basic Concepts of Cardiac MRI Physics, Image Acquisition and Safety

Familiarize

What can CMR provide for your patients and how to implement it in your practice?


- 55-year-old morbidly obese man with a rumbling diastolic murmur at the upper left sternal border with an enlarged RV on echo
- What do we order?

What can CMR do for you?




- 67-year-old woman with history of EtOH abuse, IVDA, esophageal varices who presents with systolic murmur at apex with worsening dyspnea on exertion
- What do we order?

What can CMR do for you?





- 48-year-old man with history of syncope with exercise and LVH on ECG and Echo?
- What do we order?

What can CMR do for you?




- 41-year-old man with worsening dyspnea and fatigue with an early diastolic murmur and undifferentiated echo density on TTE
- What do we order?

What can CMR do for you?





Basics of MRI

- First MRI in human subject was in 1977
- 2/3 of body is composed of water (H₂O)
- Hydrogen is the most important element for MR imaging




MR System Components



Main Magnet

- Strong, constant magnetic field
- Defines the strength of the MR System
- 1 Tesla is 20,000 times the Earth's magnetic field




Gradient Coils

- Generate a magnetic field
- They are within in the MRI system
- Generate alteration in the MR field
- Aligned in variety of different directions—gradient in all three directions
- Strength is defined as the steepness of its slope (mT/m)

Radiofrequency Coils

- Transmitter RF Coils
 - Smaller amplitude than other fields
 - Generate RF magnetic field
- Receiver RF Coils receive the wave to generate MRI image



Origin of the MR signal



Water


Fat

^{31}P ^{23}Na ^{13}C

NUCLEAR SPIN


Small magnetic field for
each proton

MAGNETIC MOMENT



Magnetic moments
are randomly oriented

MAGNETIC FIELD
Magnetic field



Larmor Equation


Resonance Principle : Some nuclei are magnetic :

Hydrogen H - 1

Carbon C - 13

Fluorine F - 19

Phosphorus P - 31



Precession Frequency

$$\omega = \gamma * B$$

γ = Gyromagnetic Ratio
(depends on nuclei,
e.g. protons: 42 MHz/T)

B = Magnetic Field Strength

Precession Frequency:


64 MHz at 1.5T

128 MHz at 3.0T

Scanner Magnetization


Patient + Magnet :

Without magnetic field :





No net magnetization

With magnetic field :



Low net magnetization


Excitation Pulse



Saturation Pulse


Saturation Pulse

90°



MR Relaxation

Relaxation



After the rf pulse
 M_0 returns to
equilibrium

Longitudinal

Transverse

M_z



M_{xy}

T1


T2*

T1 Relaxation

T1 Relaxation




T2 Time



T1 and T2 Weighting Imaging

Dark Blood T1 Spin Echo



T1 spin echo characteristics:

- *Fat = high signal intensity*
- *Moving blood = low signal intensity*
- *Water = intermediate signal intensity*

Dark Blood T2 Spin Echo with Fat Suppression (FS)



T2 w/ FS spin echo characteristics:

- *Fat = low signal intensity*
- *Moving blood = low signal intensity*
- *Water = high signal intensity*

Siemens Altea 1.5T




MRI Safety



Cardiac MRI Contraindications – The Magnet is ALWAYS ON!!!

- Cerebral Aneurysm Clips.
- Pacemakers/ICDs (relative). New MRI-conditional systems are now available.
- Pulmonary artery catheters.
- Cochlear Implants.
- Retained metallic foreign bodies.
- All prosthetic valves are safe, including TAVR (exception pre 1968 Starr Edwards Valve).
- Severe renal impairment ($\text{GFR} < 30$) → can't use Gadolinium






Uniqueness of CMR Imaging



Parameters	Values
LVEF (%)	42 (55 – 70)
LVEDVi (ml/m ²)	112 (68-103)
LVESVi (ml/m ²)	65 (19 – 41)
LV Mass index (g/m ²)	103 (59 – 93)








Valve + Biventricular Function

Structural Remodeling

Flow and Velocities

Perfusion

Tissue Characterization



3D Anatomy

T1 Mapping

T2 Mapping



LGE – Replac. Fibrosis

Interstitial Fibrosis

Function and Viability Case

- 63 M with DM with dyspnea on exertion for 3 months. Nuclear Stress test shows **fixed defect in LAD distribution (implies scar)**. LHC shows a 90% proximal LAD lesion.
- Echo prior to LHC showed an akinetic, thinned out anterior apical wall

Function and Viability Case



What is myocardial viability?

- Clinical Definitions
 - Improvement in contraction after revascularization
 - Improvement in contraction with low dose dobutamine
 - Absence of fixed thallium defect
 - Presence of glucose uptake
 - Preserved wall thickness and/or thickening
- Histologic Definition
 - Presence of living myocytes


IDEAL IMAGING METHOD:

- High spatial resolution
- High signal-to-noise
- High contrast-to-noise
- Limited imaging artifacts

Ideal Imaging Method



CMR Viability Assessment




Viability Protocol

TIME




- Insert Peripheral IV
- Place Patient In Scanner
- Cine Images
- Inject Gadolinium Contrast
- Wait 5-10 Minutes
- Delayed Enhancement Images


Late Gadolinium Enhancement



Infarct Vessel and LGE CMR




Wu et al. Lancet 2001.




Wu et al. Lancet 2001.

Revascularization Protocol





Kim et al. NEJM 2000.

LGE Determines Myocardial Viability & Predicts Recovery of Function After Revascularization




Ischemic Enhancement Pattern


A. Subendocardial Infarct




B. Transmural Infarct




LGE and Myocardial Viability




CMR Detects Subendocardial Infarcts Missed by SPECT




Post Revascularization



75F with PMH of HTN, CKD3, A Fibrillation
presets with SOB




Cardiomyopathy Assessment



- ✓ 3D visualization of the heart & thoracic structures
- ✓ Quantification of cardiac volumes and function (gold standard)
- ✓ Accurate flow quantification (VHD)
- ✓ Coronary and microvascular stress perfusion
- ✓ Determining Etiology
 - ✓ Tissue characterization: MI, scar, fatty infiltration, thrombus, iron
- ✓ Prognosis / Risk assessment


Quantification

Quantification of Ventricular Function by CMR






Volume = Area x Thickness



CMR in casts of cadaveric hearts




CMR volumetry validated:

- Animals
 - In vitro
 - In vivo
 - Ex vivo
- Superior to ECHO
- Highly accurate
 - Highly reproducible
 - Low intra-observer variability
 - Low inter-observer variability
 - LVEF: 2-7%
 - Low inter-study variability



Zoghbi WA et al. J Am Soc Echocardiogr. 2017 Apr;30(4):303-371.

Gold Standard to RV Volume, Mass, and Function

CMR is Reference Standard for Right Heart Volumes, Mass, Function




C No geometric assumptions




Buechel. European Heart Journal (2012) 33, 949–960

Cardiomyopathy Assessment




- ✓ 3D visualization of the heart & thoracic structures
- ✓ Quantification of cardiac volumes and function (gold standard)
- ✓ Accurate flow quantification (VHD)
- ✓ Coronary and microvascular stress perfusion
- ✓ Determining Etiology
 - ✓ Tissue characterization: MI, scar, fatty infiltration, thrombus, iron
- ✓ Prognosis / Risk assessment

LGE Can Help Identify Underlying Etiology




Hyperenhancement that do not fit with ischemic injury




Etiology of Cardiomyopathy and Prognosis

1230 pts with cardiomyopathy; mean follow-up of 4.4 years, 417 patients died; 57 underwent cardiac transplantation.




Felker. N Engl J Med 2000;342:1077-84.


Non-Ischemic Cardiomyopathies




Our patient




Amyloidosis





- 49 year old woman with worsening dyspnea with episodes of pre-syncope.




Cine Images





Late Gadolinium Enhancement





Cardiomyopathy Case




Late Gadolinium Enhancement





Mid wall HCM




Apical HCM




Apical HCM LGE



HCM and LGE




Chan et al, Circulation 2014.



LGE was associated with:
1. Sudden Cardiac Death
2. Endstage HCM


LGE and ICD in HCM



- 42 year old man with episodes of syncope



ARVD



ARVD Criteria

MAJOR CRITERIA

By MRI:


- Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
- *and* 1 of the following:
 - Ratio of RV end-diastolic volume to BSA ≥ 110 mL/m² (male) or ≥ 100 mL/m² (female)
 - *or* RV ejection fraction $\leq 40\%$

MINOR CRITERIA


By MRI:

- Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
- *and* 1 of the following:
 - Ratio of RV end-diastolic volume to BSA ≥ 100 to <110 mL/m² (male) or ≥ 90 to <100 mL/m² (female)
 - *or* RV ejection fraction $>40\%$ to $\leq 45\%$


Regurgitant Jet Assessment and Quantification



Quantification of
Aortic Regurgitation
is done by
2D Phase Contrast
@ Aortic Root




Phase Contrast CMR




- Strong correlation
 - In-vivo
 - LV SV in subjects w/out MR
 - SV by Fick & thermodilution
 - Doppler
 - In-vitro
 - Flow phantoms

Hundley WG. *Am J Cardiol*. 1995;75:1250–1255.
 Bogren HG. *Am Heart J*. 1989;117:1214–1222.
 Chatzimaroudis GP. *J Cardiovasc Magn Reson*. 2001;3:11–19.
 Van Rossum AC. *Eur Heart J*. 1991;12:117–126.
 Kondo C. *AJR Am J Roentgenol*. 1991;157:9–16.




Quantification

Quantification of Ventricular Function by CMR





$$\text{Volume} = \text{Area} \times \text{Thickness}$$



Zoghbi WA et al. J Am Soc
Echocardiogr. 2017 Apr;30(4):303-371.

Flow Mapping: Direct quantification Antegrade & Retrograde Volumes across Semilunar Valves



Lopez-Mattei. Methodist DeBakey Cardiovasc J. 2013 Jul-Sep;9(3):142-8

MR Assessment




Figure 7 CMR technique for assessment of great vessel forward and retrograde flow. Left side of the figure demonstrates a phase-contrast acquisition performed in the aortic root. This produces a set of two cine images at matched anatomic locations that provide differing information: a magnitude image that provides anatomic reference (A) and velocity or phase map with pixel values linearly related to velocity and direction of flow (B). On postprocessing, via drawing a region of interest around the aortic root (red circles), a flow versus time graph is generated (C), which can be used to compute forward (red arrow) and reverse flow (yellow arrow). In this example of AR, the reverse flow represents the directly measured volume of AR. The right side of the figure demonstrates the same, performed at the PA trunk to derive PA flow.






Figure 8 Example CMR method for quantification of MR. The volume of the LV is calculated during end-diastole (LVEDV) and during end-systole (LVESV) via the methodology demonstrated in Figure 6. The total volume of blood ejected from the LV, LV SV, is computed as the difference between LV end-diastolic volume and LV end-systolic volume. In this example LV SV is 150 mL. The volume of blood crossing the aortic (AO) valve is measured by performance of a phase-contrast acquisition in the aorta (as detailed in Figure 6); in this example, 80 mL. The mitral RVol (MRVol) is computed as the difference between the LV SV and aortic forward SV; in this example, 70 mL.

$$\text{Mitral Reg Vol} = \text{LV stroke volume} - \text{Aortic forward flow volume}$$


End-Diastole



End-Systole




Pericardial Disease



Pericardial Disease



CENTRAL ILLUSTRATION: Spectrum of Pericardial Disease



Chetrit, M. et al. J Am Coll Cardiol Img. 2019;13(6):1422-37.

Role of CMR in Cardiac Mass Evaluation

Cardiac Masses



	T1-weighted	T2-weighted	Post Contrast
Myxoma	Isointense, heterogeneous	Hyperintense, heterogeneous	Heterogeneous enhancement
Papillary fibroelastoma	Isointense	Hyperintense	Hyperintense
Rhabdomyoma	Iso- or hyperintense	Slightly hyperintense	Hyperintense
Fibroma	Iso- or hyperintense	Hypointense	Hyperintense
Hemangioma	Isointense	Hyperintense, heterogeneous	Hyperintense or heterogeneous
Paraganglioma	Iso- or hypointense	Hyperintense	Hyperintense
Intravenous leiomyomatosis	Isointense	Isointense	Heterogeneous
Bronchogenic cyst	Hypointense	Hyperintense	None
Angiosarcoma	Isointense, with hyperintense areas	Iso- or hyperintense	Hyperintense
Undifferentiated sarcoma	Isointense	Isointense	Nonspecific
Rhabdomyosarcoma	Isointense	Isointense, heterogeneous	Central nonenhancing areas
Osteosarcoma	Hyperintense	Hyperintense	Nonspecific
Malignant fibrous histiocytoma	Isointense	Hyperintense, heterogeneous	Nonspecific
Leiomyosarcoma	Isointense	Hyperintense	Nonspecific
Fibrosarcoma	Isointense, heterogeneous	Hyperintense	Central nonenhancing areas
Lymphoma	Hypo- or isointense	Hyperintense	Variable

Summary

